September 2026 Research Update

Studies this month leaned toward a practical message: after cholesteatoma surgery, some people still have hearing gaps or residual disease, and structured follow-up can identify who may benefit from a second operation or a hearing implant. In children, residual cholesteatoma was more common in more advanced disease and tended to be found in specific hard-to-see areas. In adults, a review suggested that adding obliteration to canal wall up surgery often reported fewer recurrences, but the available evidence was not high quality. [1] [2] [3]

One cohort of 177 patients focused on what happens after primary tympanoplasty for acquired cholesteatoma and found that over half had suboptimal hearing by their hearing test measure. Among those with poorer hearing, many met guideline-based criteria for either revision tympanoplasty, an implantable hearing device (including cochlear implant, Baha, or VSB), or both, highlighting that postoperative reassessment can open additional options that are not obvious right after the first operation. [1]

In pediatric congenital cholesteatoma, residual disease after the first surgery increased as Potsic stage increased, with stage 4 (mastoid extension) standing out as a higher-risk group. Residual cholesteatoma was often located around the stapes and tympanic sinus, which matters because these are areas where tiny remnants can be difficult to detect during the first surgery. [2]

A systematic review comparing canal wall up surgery with and without obliteration reported that most included studies found lower recurrence or residual rates when obliteration was added. At the same time, the review emphasized that the studies were heterogeneous and not high-level evidence, so the size of the benefit and which patients benefit most remain uncertain. [3]

A separate surgical case series described canal wall down tympanomastoidectomy using two pedicled flaps to pack the mastoid cavity and reported a 100% dry ear rate over 2 to 7 years, with hearing improvement in many patients and no reported recurrences in follow-up. Because this report did not include a comparison group, it mainly adds a description of one center's longer-term outcomes with a specific technique rather than proving it is better than other approaches. [4]

For patients and caregivers, this set of studies adds detail to what follow-up is trying to catch: ongoing hearing problems and residual cholesteatoma that may not be visible or symptomatic early on. The clearest near-term takeaway is that hearing outcomes after surgery can vary, and some people may fit criteria for additional procedures or implantable hearing devices when formally reassessed. The possible advantage of obliteration in canal wall up surgery is still mainly a research question because better-quality comparative studies are missing. [1] [3]

For families dealing with congenital cholesteatoma, this month strengthens the idea that disease stage and specific middle-ear locations can affect the chance of residual disease being found later. That information does not predict what will happen for any one child, but it helps explain why some surgeons plan second-look strategies more often in higher-stage cases and why careful attention to areas like the stapes region matters. [2]

This month, studies looking at possible drivers of cholesteatoma pointed in a similar direction: no single simple factor fully explains who has more extensive disease or complications. The bacteria or fungi grown from surgical samples did not match disease stage, while habitual sniffing and chronic health conditions were linked to distinct patterns such as contralateral ear changes or higher complication risk. Together, these findings frame cholesteatoma as influenced by anatomy, pressure changes, and overall health, not just infection alone. [5] [6] [7]

A prospective study of patients undergoing tympanomastoid surgery found that aerobic bacteria were common in samples, fungi were also seen in a substantial minority, and anaerobes were uncommon. Importantly, the presence of aerobic, anaerobic, or fungal growth did not differ in a meaningful way across EAONO/JOS stages, suggesting that culture results did not act as a marker of how advanced the cholesteatoma was. [5]

In adults with acquired pars flaccida cholesteatoma, habitual sniffing was linked to better-developed mastoid air cells but more frequent abnormalities in the opposite ear. The authors interpreted this as supporting a subgroup in which repeated pressure changes (negative pressure loading) may shape how disease appears in both ears. [6]

A large retrospective study from Western Yunnan reported that about one-third of patients had complications, and that having chronic underlying diseases such as hypertension or diabetes was an independent risk factor. The same analysis found that method of medical expense payment was an independent protective factor, suggesting that access or financial factors could also relate to complication patterns in that setting. [7]

For patients, these studies add context for why cholesteatoma can look different from person to person. Germs found on culture may be important for managing infection symptoms, but in this month s data they did not track with how advanced the cholesteatoma was, so culture does not act like a staging test. Other factors such as pressure-related habits and general health conditions were linked to disease patterns or complications in observational data, which may matter more for understanding risk than for making immediate care changes. [5] [6] [7]

What remains uncertain is whether changing any of these factors would change outcomes, because these studies mainly compared groups rather than testing an intervention. Even so, they help clarify that cholesteatoma is not simply an infection problem and that broader health and ear pressure dynamics may be part of the picture for some people. [6] [7]

This month added both rare examples and broader pooled data about cholesteatoma affecting the brain area or facial nerve. The case reports showed that cholesteatoma can sometimes be part of complicated infections or skull-base defects, but they also illustrated that patients may recover with combinations of infection control, ear surgery, and reconstruction tailored to the situation. A meta-analysis focused on petrous apex cholesteatoma suggested that facial nerve function improves after surgery in about half of reported cases, with certain factors linked to worse recovery. [8] [9] [10] [11]

Across individual reports, cholesteatoma appeared alongside unusual or severe problems including recurrent meningitis, cerebrospinal fluid ear leakage, and a brain abscess pattern that was thought to spread along cranial nerves. In each case, the ear source was treated surgically (such as tympanomastoidectomy or skull-base repair) alongside prolonged infection management when needed, and follow-up imaging or visits described resolution or stable recovery within the reported timeframes. [8] [9] [10]

Facial nerve weakness was described both as a rare presentation in external auditory canal cholesteatoma and as an outcome of petrous apex cholesteatoma in pooled literature. One surgical case reported improvement in facial movement after decompression, while the meta-analysis reported a 53% overall postoperative improvement rate and identified longer duration (at least 1 year), more severe weakness before surgery, and facial nerve discontinuity as factors linked to lower odds of improvement. [12] [11]

Two additional reports added biological detail about how cholesteatoma damages nearby structures. A postmortem temporal bone analysis found that areas with stronger inflammation were paired with thicker overgrown cholesteatoma lining and erosion of an ossicle, and an ex vivo study in children showed major ossicle damage on 3D micro-CT while standard markers did not show clear squamous epithelium invading the ossicle surface. Together, these reports reinforce that inflammation and bone damage can vary by location within the ear. [13] [14]

For patients and caregivers, these reports mainly add awareness of what doctors may look for when symptoms are unusual, such as neurologic symptoms or facial weakness. The case reports do not show how often these events occur, but they illustrate possible pathways and the types of combined treatments used when complications arise. The meta-analysis provides a broader view that facial nerve function can improve after surgery in many reported petrous apex cases, and it helps clarify which features have been linked to poorer recovery in the published literature. [8] [11]

These findings matter most for people with complicated cholesteatoma involving the skull base or facial nerve, and they are less directly relevant to typical middle-ear cholesteatoma without nerve symptoms. What remains uncertain is how well results from pooled case-based literature apply to any individual patient, and the biology reports are early evidence that does not yet translate into a test or a new treatment. [12] [13] [14]